18 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2037
Next term end
13
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2038 · High confidence
Also notable
Ends Feb 2038 · High confidence
Also notable
Ends no later than Feb 2039 · Medium confidence
Nucleic Acid Molecules Encoding Activin Receptor Type Iia Variants
US 11,717,558
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2038.
Activin Receptor Type Iia Variants and Methods of Use Thereof
US 11,090,361
The most cited patent in this portfolio, cited by 17 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2038.
Activin Receptor Type Iia Variants and Methods of Use Thereof
US 11,484,573
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 8, 2027The maintenance fee for Nucleic Acid Molecules Encoding Activin Receptor Type Iia Variants (US 11,717,558) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Activin Receptor Type Iib Variants and Methods of Use Thereof (US 11,884,715) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for GDNF Fusion Polypeptides and Methods of Use Thereof (US 11,912,750) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
What they patent
The 5 largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Activin Receptor Type Iia Variants and Methods of Use Thereof | 4 in force | to Apr 2038 |
| Activin Receptor Type Iib Variants and Methods of Use Thereof | 2 in force | to Apr 2041 |
| GDNF Fusion Polypeptides and Methods of Use Thereof | 2 in force | to Nov 2037 |
| Methods of Treating Cardiovascular-Related Disease | 1 in force | to Oct 2043 |
| Activin Receptor Type II Chimeras and Methods of Use Thereof | 1 in force | to Dec 2042 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,013,785 | Activin Receptor Type Iia Variants and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,912,750 | GDNF Fusion Polypeptides and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,350,313 | Activin Receptor Type Iia Variants and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,404,313 | GDNF Fusion Polypeptides and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,582,700 | Activin Receptor Type Iia Variants and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,090,361 | Activin Receptor Type Iia Variants and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,717,558 | Nucleic Acid Molecules Encoding Activin Receptor Type Iia Variants In force · High confidence | In force | High confidence | |
| US 12,269,858 | Activin Receptor Type Iib Variants and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,484,573 | Activin Receptor Type Iia Variants and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,884,715 | Activin Receptor Type Iib Variants and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 20 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.